ClinicalTrials.gg
CompletedNCT01661270AFLAMEUpdated Oct 18, 2016Results posted

A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy

A Phase 3 interventional study of Aflibercept and Placebo in Colorectal Cancer Metastatic, sponsored by Sanofi. Completed at 37 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-18.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing aflibercept in Colorectal Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. aflibercept · Colorectal Neoplasms.

Enrollment
3rd of 24
332 · median 63
Started
2012
with 6 others
Phase 3
4 of 24
none open now
Registered
9th of 24
by date
Lead sponsor
8 of 24
Sanofi

Among the 24 studies testing aflibercept in Colorectal Neoplasms, this one is the 3rd largest by enrollment, is one of 7 that started in 2012, is one of 4 in phase 3, and was the 9th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 24 studies testing aflibercept in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing aflibercept in Colorectal Neoplasms, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the improvement in progression-free survival (PFS) of aflibercept versus placebo in participants with metastatic colorectal cancer treated with FOLFIRI as second-line treatment for metastatic disease.

Secondary Objectives:

To compare the overall survival (OS) in the 2 treatment arms. To compare the overall response rate (ORR) in the 2 treatment arms. To assess the safety profile of the 2 treatment arms. To assess immunogenicity of intravenous (IV) aflibercept in selected centers.

Read the detailed description

Screening occurred from signed informed consent to randomization (up to 21 days). A treatment cycle was defined as a 2 week-period. All participants were followed during the study treatment and follow-up period until death or study cut off date, which ever comes first.

03

Conditions studied

  • Colorectal Cancer Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological proven adenocarcinoma of the colon or rectum.
  • disease that was not amenable to potentially curative treatment.
  • One and only one prior chemotherapeutic regimen for metastatic disease. This prior chemotherapy must be an oxaliplatin containing regimen. Participants who were within 6 months of completion of oxaliplatin based chemotherapy were eligible.

Exclusion criteria

Exclusion criteria:

  • Prior therapy with irinotecan.
  • (ECOG) performance status >1.
  • Less than 28 days elapsed from prior radiotherapy, from prior surgery and prior chemotherapy to the time of randomization. Less than 42 days elapsed from prior major surgery to the time to randomization.
  • Adverse events (with exception of alopecia, peripheral sensory neuropathy grade ≤ 2 and those listed in specific exclusion criteria) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria [] v.3.0) at the time of randomization.
  • Age \<18 years.
  • History of , uncontrolled spinal cord compression, or carcinomatous meningitis or new evidence of brain or .
  • Other prior . Adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or any other cancer from which the participants had disease free for > 5 years were allowed.
  • Participation in another clinical trial with an drug and any concurrent treatment with any investigational drug within 30 days prior to randomization.
  • Any of the following within 6 months prior to randomization: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, Functional Classification (NYHA) class III or IV congestive heart failure, stroke or .
  • Any of the following within 3 months prior to randomization: treatment resistant peptic or duodenal ulcer disease, erosive oesophagitis or gastritis, grade 3 or 4 gastrointestinal bleeding/hemorrhage, gastrointestinal perforation/fistula, abdominal abscess, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event.
  • Participants who had given high dose of aspirin or non steroidal anti-inflammatory agents (NSAIDS) or high within 4 weeks prior to randomization. The definition of "high dose" was to be based on the investigator's judgment.
  • Occurrence of deep vein thrombosis within 4 weeks, prior to randomization.
  • Inadequate organ or bone marrow function.
  • Pregnant or breast-feeding woman. Positive serum or urine pregnancy test prior to randomization. Participants with reproductive (M/F) who were not agree to use accepted and effective method of during the study treatment period and for at least 6 months following completion of study treatment.
  • Uncontrolled hypertension.
  • Urine Protein: creatine ratio (UPCR) >1 on morning spot urinalysis or proteinuria > 500mg/24 hours.
  • Participants on anticoagulant therapy with unstable dose of warfarin and/or having an out-of-therapeutic range (INR) (>3) within 4 weeks prior to randomization.
  • Evidence of bleeding diathesis or underlying coagulopathy.
  • Known dihydropyrimidine dehydrogenase deficiency.
  • Predisposing colonic or small bowel disorder in which the symptoms were uncontrolled as indicated by baseline of > 3 loose stools daily.
  • Prior history of chronic enteropathy, inflammatory enteropathy, chronic diarrhea, unresolved bowel obstruction/sub-obstruction, more than hemicolectomy, extensive small intestine resection with chronic diarrhea.
  • History of anaphylaxis or known intolerance to atropine sulphate or loperamide or appropriate antiemetics to be administered in conjunction with FOLFIRI.
  • Treatment with concomitant anticonvulsant agents that were cytochrome P450 3A4 () inducers (phenytoin, phenobarbital, carbamazepine), unless discontinued > 7 days.
  • Participants with known Gilbert's syndrome.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
332 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo for aflibercept intravenous (IV) infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m\^2 IV infusion and leucovorin 400 mg/m\^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m\^2 followed by continuous IV infusion 2400 mg/m\^2.

    Drug: Placebo

  • Experimental
    Aflibercept

    Aflibercept 4 mg/kg IV infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m\^2 IV infusion and leucovorin 400 mg/m\^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m\^2 followed by continuous IV infusion 2400 mg/m\^2.

    Drug: Aflibercept

Interventions

  • Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous

    Also known as: AVE0005, Zaltrap

  • DrugPlacebo

    Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time interval from the date of randomization to the date of first observation of either tumor progression or death due to any cause. Tumor assessment was performed by Independent Review Committee (IRC) as per response evaluation criteria in solid tumors (RECIST) version 1.0. Progression was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study or absolute increase and at least 5 mm, progression of existing non-target lesions, or presence of new lesions. PFS was calculated by Kaplan-Meier estimates.

    Time frame: 26.7 months

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the earliest between the last date of the participants was known to be alive and the study cut-off date. Analysis was performed by Kaplan-Meier method.

    Time frame: 31.6 months

  2. Percentage of Participants With Objective Response

    Objective response rate was defined as the proportion of participants with confirmed complete response (CR) or confirmed partial response (PR), as assessed by Investigators and the IRC according to RECIST 1.0 criteria, relative to the total number of participants in the relevant analysis population. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions.

    Time frame: 26.6 months

07

Results

Posted Nov 26, 2015

Participant flow

The study was conducted at 37 centers in 5 countries. A total of 332 participants were randomized between 17 July 2012 and 18 March 2014.

Participant flow — Overall Study
MilestonePlaceboAflibercept
Started109223
Adverse event2647
Disease progression67118
Physician decision18
Participant's request1548
Other reasons02
Completed109223
Not completed00

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS was defined as the time interval from the date of randomization to the date of first observation of either tumor progression or death due to any cause. Tumor assessment was performed by Independent Review Committee (IRC) as per response evaluation criteria in solid tumors (RECIST) version 1.0. Progression was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study or absolute increase and at least 5 mm, progression of existing non-target lesions, or presence of new lesions. PFS was calculated by Kaplan-Meier estimates.

Time frame:
26.7 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsPlaceboAflibercept
Progression-free Survival (PFS)5.59 (4.632 to 6.111)6.93 (6.045 to 7.655)
SecondaryOverall Survival (OS)

OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the earliest between the last date of the participants was known to be alive and the study cut-off date. Analysis was performed by Kaplan-Meier method.

Time frame:
31.6 months
Reported as:
Median · months
Overall Survival (OS)
monthsPlaceboAflibercept
Overall Survival (OS)11.93 (10.086 to 14.292)14.59 (13.175 to 16.460)
SecondaryPercentage of Participants With Objective Response

Objective response rate was defined as the proportion of participants with confirmed complete response (CR) or confirmed partial response (PR), as assessed by Investigators and the IRC according to RECIST 1.0 criteria, relative to the total number of participants in the relevant analysis population. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions.

Time frame:
26.6 months
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response
percentage of participantsPlaceboAflibercept
Percentage of Participants With Objective Response3.7 (NA to NA)18.4 (13.3 to 23.5)

Adverse events

Collected over All AE collected from signature of informed consent upto resolution/stabilization/death regardless of seriousness/relationship to IMP.After cutoff date for OS,only ongoing AE & SAE were followed until resolution,stabilization/2 follow-ups(about 4 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Only—9/33 (27.3%)32/33 (97%)
Aflibercept Only—30/111 (27%)109/111 (98.2%)
Mixed Administration (Placebo and Aflibercept)—43/188 (22.9%)188/188 (100%)
Most frequent serious events
Showing 10 of 82
Most frequent serious events
EventPlacebo OnlyAflibercept OnlyMixed Administration (Placebo and Aflibercept)
Intestinal obstructionGastrointestinal disorders3/332/1115/188
Anal abscessInfections and infestations1/331/1113/188
Lobar pneumoniaInfections and infestations1/330/1110/188
SepsisInfections and infestations1/330/1110/188
NeutropeniaBlood and lymphatic system disorders1/332/1111/188
Loss of consciousnessNervous system disorders1/330/1111/188
Venous thrombosis limbVascular disorders1/330/1110/188
DiarrhoeaGastrointestinal disorders1/332/1112/188
ThrombocytopeniaBlood and lymphatic system disorders0/332/1111/188
Deep vein thrombosisVascular disorders0/332/1110/188
Most frequent other events
Showing 10 of 55
Most frequent other events
EventPlacebo OnlyAflibercept OnlyMixed Administration (Placebo and Aflibercept)
NeutropeniaBlood and lymphatic system disorders22/3368/111135/188
NauseaGastrointestinal disorders22/3361/111110/188
VomitingGastrointestinal disorders22/3356/111107/188
DiarrhoeaGastrointestinal disorders14/3360/111122/188
LeukopeniaBlood and lymphatic system disorders20/3359/11184/188
Decreased appetiteMetabolism and nutrition disorders15/3342/11190/188
FatigueGeneral disorders9/3337/11184/188
HypertensionVascular disorders1/3343/11165/188
StomatitisGastrointestinal disorders5/3327/11160/188
EpistaxisRespiratory, thoracic and mediastinal disorders0/3330/11138/188

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboAfliberceptTotal
Mean53.0 ± 11.355.1 ± 10.954.4 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAfliberceptTotal
Female4695141
Male63128191
08

Study locations

37 sites
  • Investigational Site Number 156003
    Beijing, 100071, China
  • Investigational Site Number 156001
    Beijing, 100142, China
  • Investigational Site Number 156002
    Beijing, 100210, China
  • Investigational Site Number 156004
    Beijing, 100853, China
  • Investigational Site Number 156016
    Chengdu, 610041, China
  • Investigational Site Number 156020
    Chongqing, 400038, China
  • Investigational Site Number 156021
    Fuzhou, 350014, China
  • Investigational Site Number 156008
    Guangzhou, 510060, China
  • Investigational Site Number 156010
    Hangzhou, 310003, China
  • Investigational Site Number 156011
    Hangzhou, 310009, China
  • Investigational Site Number 156009
    Hangzhou, 310016, China
  • Investigational Site Number 156015
    Harbin, 150081, China
  • Investigational Site Number 156012
    Nanjing, 210002, China
  • Investigational Site Number 156013
    Nanjing, 210029, China
  • Investigational Site Number 156006
    Shanghai, 200032, China
  • Investigational Site Number 156007
    Shanghai, 200032, China
  • Investigational Site Number 156014
    Shenyang, 110001, China
  • Investigational Site Number 156005
    Tianjin, 300060, China
  • Investigational Site Number 156019
    Wuhan, 430022, China
  • Investigational Site Number 156018
    Wuhan, 430030, China
  • Investigational Site Number 156017
    Xi'An, 710032, China
  • Investigational Site Number 344002
    Hong Kong, Hong Kong
  • Investigational Site Number 344001
    Shatin, Nt, Hong Kong
  • Investigational Site Number 392006
    Amagasaki-Shi, Japan
  • Investigational Site Number 392003
    Bunkyo-Ku, Japan
  • Investigational Site Number 392004
    Bunkyo-Ku, Japan
  • Investigational Site Number 392009
    Gifu-Shi, Japan
  • Investigational Site Number 392002
    Kitaadachi-Gun, Japan
  • Investigational Site Number 392001
    Kobe-Shi, Japan
  • Investigational Site Number 392005
    Kochi-Shi, Japan
  • Investigational Site Number 392007
    Kumamoto-Shi, Japan
  • Investigational Site Number 392008
    Nagakute-Shi, Japan
  • Investigational Site Number 392010
    Takatsuki-Shi, Japan
  • Investigational Site Number 702002
    Singapore, 119228, Singapore
  • Investigational Site Number 702001
    Singapore, 169610, Singapore
  • Investigational Site Number 158003
    Taipai, 10043, Taiwan
  • Investigational Site Number 158002
    Taipei, Taiwan
09

References and documents

Publications

  • Li J, Xu R, Qin S, Liu T, Pan H, Xu J, Bi F, Lim R, Zhang S, Ba Y, Bai Y, Fan N, Tsuji A, Yeh KH, Ma B, Wei V, Shi D, Magherini E, Shen L. Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. Future Oncol. 2018 Aug;14(20):2031-2044. doi: 10.2217/fon-2017-0669. Epub 2018 Aug 17. Erratum In: Future Oncol. 2019 Feb;15(4):451. doi: 10.2217/fon-2017-0669c1. PubMed 30117334 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Oct 2014 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2012
First posted
Aug 9, 2012
Start
Jul 2012
Primary completionActual
Oct 2014
CompletionActual
Jul 2015
Results first posted
Nov 26, 2015
Last update
Oct 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01661270
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 9, 2012
Start date
Jul 2012
Primary completion
Oct 2014
Completion
Jul 2015
Results posted
Nov 26, 2015
Last update
Oct 18, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion